Foralumab for Multiple Sclerosis youtu.be/1KlKHHE9_aY?...
Foralumab for Multiple Sclerosis
YouTube video by Dr. Brandon Beaber
youtu.be
August 27, 2025 at 10:24 PM
Foralumab for Multiple Sclerosis youtu.be/1KlKHHE9_aY?...
Upcoming study of the monoclonal antibody foralumab to reduce microglial activation in Alzheimer’s, following “promising results in MS patients” and a mouse model of Alzheimer’s.
Can this nasal spray slow down Alzheimer's? One couple is helping scientists find out
Joe Walsh is the first Alzheimer's patient to be treated with an experimental nasal spray designed to reduce inflammation in the brain.
www.npr.org
May 30, 2025 at 8:25 PM
Upcoming study of the monoclonal antibody foralumab to reduce microglial activation in Alzheimer’s, following “promising results in MS patients” and a mouse model of Alzheimer’s.
100% agree.
Hoping Tiziana’s nasal foralumab is approved soon for MS and Alzheimer’s.
Hoping Tiziana’s nasal foralumab is approved soon for MS and Alzheimer’s.
July 26, 2025 at 6:15 PM
100% agree.
Hoping Tiziana’s nasal foralumab is approved soon for MS and Alzheimer’s.
Hoping Tiziana’s nasal foralumab is approved soon for MS and Alzheimer’s.
Foralumab for Multiple Sclerosis
www.youtube.com/watch?v=1KlK...
www.youtube.com/watch?v=1KlK...
Foralumab for Multiple Sclerosis
YouTube video by Dr. Brandon Beaber
www.youtube.com
September 22, 2025 at 6:46 AM
Foralumab for Multiple Sclerosis
www.youtube.com/watch?v=1KlK...
www.youtube.com/watch?v=1KlK...
Looks like the company behind foralumab is thinking along these lines too—they advertise a planned application for IND for Long Covid!
Also sets out how to apply to their expanded access program 👀
Also sets out how to apply to their expanded access program 👀
Intranasal Foralumab - Tiziana Life Sciences
www.tizianalifesciences.com
May 31, 2025 at 1:46 PM
Looks like the company behind foralumab is thinking along these lines too—they advertise a planned application for IND for Long Covid!
Also sets out how to apply to their expanded access program 👀
Also sets out how to apply to their expanded access program 👀
Foralumab is designed to reduce inflammation in the brain which experts say is a common feature of many neurologic diseases. 🤞
apple.news/Ad624oTJWR8O...
apple.news/Ad624oTJWR8O...
Mass. man first in country to try new Alzheimer's nasal spray treatment — WCVB
Doctors at Brigham and Women's said they want to test foralumab on a larger group of Alzheimer's patients.
apple.news
February 10, 2025 at 11:39 PM
Foralumab is designed to reduce inflammation in the brain which experts say is a common feature of many neurologic diseases. 🤞
apple.news/Ad624oTJWR8O...
apple.news/Ad624oTJWR8O...
- some long term DMT used already in #MS (from b-cell therapies like daratumumab, belimumab or inebilizumab, to newest t-cell like foralumab and rapamycin).
April 20, 2026 at 9:32 AM
- some long term DMT used already in #MS (from b-cell therapies like daratumumab, belimumab or inebilizumab, to newest t-cell like foralumab and rapamycin).
Mass. man first in country to try new Alzheimers nasal spray treatment | Click on the image to read the full story
Mass. man first in country to try new Alzheimers nasal spray treatment
Doctors at Brigham and Women's said they want to test foralumab on a larger group of Alzheimer's patients.
www.wcvb.com
February 10, 2025 at 10:50 PM
Mass. man first in country to try new Alzheimers nasal spray treatment | Click on the image to read the full story
Nasal spray foralumab is in clinical trials at Brigham and Womens for Alzheimers. Could someone tell Trump that slashing indirect costs on NIH grants is a total buzzkill for trials like this?
February 12, 2025 at 2:31 PM
Nasal spray foralumab is in clinical trials at Brigham and Womens for Alzheimers. Could someone tell Trump that slashing indirect costs on NIH grants is a total buzzkill for trials like this?
#MS
#MultipleSclerosis
Novartis has new trial for nonactive SPMS recruiting soon
Key inclusions
PPMS and SPMS
Ages 18-60 inclusive
Disease less than 15 years
Lumbar punctures required
Unfortunately I do not qualify for this one.
Waiting on #foralumab trial
clinicaltrials.gov/study/NCT066...
#MultipleSclerosis
Novartis has new trial for nonactive SPMS recruiting soon
Key inclusions
PPMS and SPMS
Ages 18-60 inclusive
Disease less than 15 years
Lumbar punctures required
Unfortunately I do not qualify for this one.
Waiting on #foralumab trial
clinicaltrials.gov/study/NCT066...
ClinicalTrials.gov
clinicaltrials.gov
November 19, 2024 at 9:25 PM
#MS
#MultipleSclerosis
Novartis has new trial for nonactive SPMS recruiting soon
Key inclusions
PPMS and SPMS
Ages 18-60 inclusive
Disease less than 15 years
Lumbar punctures required
Unfortunately I do not qualify for this one.
Waiting on #foralumab trial
clinicaltrials.gov/study/NCT066...
#MultipleSclerosis
Novartis has new trial for nonactive SPMS recruiting soon
Key inclusions
PPMS and SPMS
Ages 18-60 inclusive
Disease less than 15 years
Lumbar punctures required
Unfortunately I do not qualify for this one.
Waiting on #foralumab trial
clinicaltrials.gov/study/NCT066...
Upcoming videos:
8/13/25: Famous Athletes with MS
8/20/25: Why Doctors Check Reflexes
8/27/25: Foralumab
Let me know if you have video suggestions
8/13/25: Famous Athletes with MS
8/20/25: Why Doctors Check Reflexes
8/27/25: Foralumab
Let me know if you have video suggestions
August 7, 2025 at 3:32 AM
Upcoming videos:
8/13/25: Famous Athletes with MS
8/20/25: Why Doctors Check Reflexes
8/27/25: Foralumab
Let me know if you have video suggestions
8/13/25: Famous Athletes with MS
8/20/25: Why Doctors Check Reflexes
8/27/25: Foralumab
Let me know if you have video suggestions
BIG news for nonactive SPMS MS Multiple Sclerosis.
Trials on east cost USA still recruiting.
stocks.apple.com/A-RlMw-pITbi...
Trials on east cost USA still recruiting.
stocks.apple.com/A-RlMw-pITbi...
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab — GlobeNewswire
BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
stocks.apple.com
January 22, 2026 at 11:46 AM
BIG news for nonactive SPMS MS Multiple Sclerosis.
Trials on east cost USA still recruiting.
stocks.apple.com/A-RlMw-pITbi...
Trials on east cost USA still recruiting.
stocks.apple.com/A-RlMw-pITbi...
Aging in MS and treatment options with Dr. Bianca Weinstock-Guttman @MSViewsandNews. Metformin, BTKis, foralumab, CAR-T. remyelination. paramagnetic rim lesions, memory problems. youtu.be/ibcVKu5Z1zk?...
Aging in MS and treatment options
YouTube video by The MS Views and News Learning Channel
youtu.be
July 14, 2025 at 8:08 PM
Aging in MS and treatment options with Dr. Bianca Weinstock-Guttman @MSViewsandNews. Metformin, BTKis, foralumab, CAR-T. remyelination. paramagnetic rim lesions, memory problems. youtu.be/ibcVKu5Z1zk?...
Nasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
March 25, 2025 at 2:28 AM
Nasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
#MS Tiziana expands number of test sites for foralumab for naSPMS.
All sites still on east coast of USA.
#MultipleSclerosis
stocks.apple.com/An1yZgJl5Rcy...
All sites still on east coast of USA.
#MultipleSclerosis
stocks.apple.com/An1yZgJl5Rcy...
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers — GlobeNewswire
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
stocks.apple.com
December 5, 2024 at 3:11 AM
#MS Tiziana expands number of test sites for foralumab for naSPMS.
All sites still on east coast of USA.
#MultipleSclerosis
stocks.apple.com/An1yZgJl5Rcy...
All sites still on east coast of USA.
#MultipleSclerosis
stocks.apple.com/An1yZgJl5Rcy...
If you have a diagnosis of mild cognitive impairment due to Alzheimer’s disease or dementia, you may be eligible for the Foralumab study. This study will look at whether the investigational drug (Foralumab) can slow or improve cognitive decline in patients with early Alzheimer’s or dementia.
July 8, 2025 at 12:16 PM
If you have a diagnosis of mild cognitive impairment due to Alzheimer’s disease or dementia, you may be eligible for the Foralumab study. This study will look at whether the investigational drug (Foralumab) can slow or improve cognitive decline in patients with early Alzheimer’s or dementia.
Good stuff… ALS, MS and Alzheimer’s.
alsnewstoday.com/news/tiziana...
alsnewstoday.com/news/tiziana...
Tiziana seeking FDA OK to launch clinical trial of foralumab in ALS
Tiziana is seeking FDA clearance for a Phase 2 clinical trial testing the safety and efficacy of its foralumab nasal spray in ALS patients.
alsnewstoday.com
March 7, 2025 at 9:29 PM
Good stuff… ALS, MS and Alzheimer’s.
alsnewstoday.com/news/tiziana...
alsnewstoday.com/news/tiziana...
#foralumab
#MultipleSclerosis
#Non active SPMS
Interesting news :
"Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program"
#MultipleSclerosis
#Non active SPMS
Interesting news :
"Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program"
Breakthrough MS Treatment Shows Promise: 100% Patient Response Rate in Expanded Trial
Tiziana's intranasal foralumab delivers positive outcomes in multiple sclerosis program, with all initial patients showing improvement or stability within 6 months.
www.stocktitan.net
February 19, 2025 at 8:29 PM
#foralumab
#MultipleSclerosis
#Non active SPMS
Interesting news :
"Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program"
#MultipleSclerosis
#Non active SPMS
Interesting news :
"Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program"
👃Pokud máte "neaktivní" sekundárně progresivní RS (SPRS), možná máte pocit, že na vás výzkum zapomněl. Většina léků je pro relabující formy. Ale teď přichází změna. Lék Foralumab, který se podává jednoduše jako nosní sprej, dosáhl v malé studii 100%...
Více:⬇️
roztrouseni.cz/nadeje-v-nos...
Více:⬇️
roztrouseni.cz/nadeje-v-nos...
Naděje v nosním spreji? Foralumab zastavil zhoršování u pacientů s progresivní RS (studie potvrzena!) | roztroušení
Pokud máte
roztrouseni.cz
January 27, 2026 at 2:00 PM
👃Pokud máte "neaktivní" sekundárně progresivní RS (SPRS), možná máte pocit, že na vás výzkum zapomněl. Většina léků je pro relabující formy. Ale teď přichází změna. Lék Foralumab, který se podává jednoduše jako nosní sprej, dosáhl v malé studii 100%...
Více:⬇️
roztrouseni.cz/nadeje-v-nos...
Více:⬇️
roztrouseni.cz/nadeje-v-nos...
#TLSA Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-announces-dosing-of-additional-patients-in-gqsrpkzstyq8.html
https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-announces-dosing-of-additional-patients-in-gqsrpkzstyq8.html
Breakthrough MS Treatment Shows Promise: 100% Patient Response Rate in Expanded Trial
Tiziana's intranasal foralumab delivers positive outcomes in multiple sclerosis program, with all initial patients showing improvement or stability within 6 months.
www.stocktitan.net
February 18, 2025 at 1:00 PM
#TLSA Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-announces-dosing-of-additional-patients-in-gqsrpkzstyq8.html
https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-announces-dosing-of-additional-patients-in-gqsrpkzstyq8.html